TVT-SECUR A Pilot Study for the Treatment of Stress Urinary Incontinence

NCT ID: NCT00463554

Last Updated: 2023-08-23

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

72 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-04-01

Study Completion Date

2007-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this study is to obtain clinical performance information on the GYNECARE TVT-SECUR\* System (Tension-free Support for Incontinence) in women with stress urinary incontinence (SUI).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The primary variable for effectiveness is \> 50% improvement on the subjective symptom Visual Analog Scale (VAS) at Visit 3/Week 5 (35 days post-surgery) to be accepted.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stress Urinary Incontinence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GYNECARE TVT-SECUR* System

A sub-urethral sling for the treatment of SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sub-urethral sling

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must be female with objective, demonstratable signs of SUI or stress predominant mixed incontinence and requires elective, primary surgical intervention.
* Must be at least 21 years old.
* Must be postmenopausal (amenorrhea) for at least 1 year or surgically sterile (bilateral salpingo-oophorectomy or tubal ligation or otherwise be incapable of pregnancy) or has a negative pregnancy test prior to study entry and has decided to cease childbearing.
* Agrees to participate in the study, including all study related procedures and evaluations and documents this agreement by signing the IRB/EC-approved informed consent

Exclusion Criteria

* Have any other coexistent pathology requiring concomitant surgery that may impact this procedure i.e. surgeries that involve the anterior vaginal wall (e.g. anterior colporrhaphy, diverticula, anterior Prolift) Any allowable concomitant surgery must be performed prior to the GYNECARE TVT SECUR System surgery.
* Have intrinsic sphincter deficiency (ISD) \[Urethral Pressure Profile (UPP) with a maximum urethral closing pressure (MUCP) \< 20cm H2O or Leak Point Pressure (LPP) \< 60\].
* Have an active urinary tract infection (UTI) or vaginal infection at time of surgery.
* Have a fixed urethra (\< 30° mobility on Q-Tip Straining Test).
* Have had prior incontinence surgery.
* Have a post-void residual volume \> 100mL.
* Have co-existent pelvic organ prolapse that is symptomatic or extends beyond the hymen.
* Have lower urinary tract pathology in the form of a fistula or diverticulum.
* Have a malignancy or with a history of malignancy within the past 5 years, except for a basal cell carcinoma that has been treated with local excision and is no longer present.
* Are on anticoagulant therapy.
* Have received an experimental drug or used an experimental medical device within 30 days prior to the planned start of treatment.
* Are deemed by the investigator as medically unfit for surgery or who in the opinion of the investigator should not be enrolled in the study because of the precautions, warnings or contraindications outlined in the GYNECARE TVT SECUR System IFU.
* Employees of the investigator or study center with direct involvement in the proposed study or other studies under the direction of that investigator or study center.
Minimum Eligible Age

21 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ethicon, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David Robinson, MD

Role: STUDY_DIRECTOR

Ethicon, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Michigan Institute of Women's Health

Dearborn, Michigan, United States

Site Status

Good Samaritan Hospital

Cincinnati, Ohio, United States

Site Status

The Institute for Female Pelvic Medicine and Reconstructive Surgery

Allentown, Pennsylvania, United States

Site Status

Vanderbilt University

Nashville, Tennessee, United States

Site Status

Helsinki University Central Hospital

Helsinki, , Finland

Site Status

University of Padova

Padua, , Italy

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Finland Italy

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

300-05-002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

TVT Worldwide Registry
NCT00453739 COMPLETED
InTone for Urinary Incontinence
NCT02543242 UNKNOWN NA